Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
SAGE documentation
Human papillomavirus (HPV)
Type of publications
NITAG documentation (137)
Reports (4)
SAGE documentation (18)
Scientific publications (13)
Systematic reviews (SYSVAC) (335)
Topics
Evidence to recommendation table (3)
GRADE table (9)
Meeting report (1)
Position paper (5)
Diseases
Human papillomavirus (HPV) (18)
Cholera (5)
COVID-19 (34)
Dengue (13)
Diphtheria (4)
Ebola (6)
Haemophilus influenzae type B (4)
Hepatitis A (11)
Hepatitis B (4)
Hepatitis E (2)
Herpes zoster (2)
Influenza (17)
Japanese encephalitis (10)
Malaria (13)
Measles (14)
Meningococcal disease (7)
Mpox (7)
Mumps (2)
Pertussis (4)
Pneumococcal disease (12)
Poliomyelitis (20)
Rabies (5)
Rotavirus (1)
RSV (Respiratory syncytial virus) (4)
Rubella (8)
Smallpox (1)
Tetanus (2)
Tick-borne encephalitis (1)
Tuberculosis (9)
Typhoid (8)
Varicella (3)
Yellow fever (3)
Show more
Publication date
2022 (3)
2017 (10)
2015 (2)
2014 (2)
2008 (1)
Available to download in languages
fr (4)
18 results found
2022
∙
SAGE
Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations
2022
∙
SAGE
Should an off-label , permissive one-dose HPV vaccine schedule for use in routine and/or multi-age cohort (MAC) catch up strategies be recommended?
2022
∙
SAGE
Human papillomavirus vaccines: WHO position paper, December 2022
2017
∙
SAGE
Efficacy of 2 vs. 3 doses of HPV vaccination in immunocompetent girls
2017
∙
SAGE
Efficacy of HPV vaccination in HIV infected girls
2017
∙
SAGE
Efficacy of' HPV vaccination in adolescent girls
2017
∙
SAGE
Human papillomavirus vaccines: WHO position paper
2017
∙
SAGE
Immunogenicity of 2 vs. 3 doses of HPV vaccination in immunocompetent girls
2017
∙
SAGE
In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines?
2017
∙
SAGE
Protection of anogenital warts conferred by HPV vaccination in immunocompetent girls
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register